OPTOMED OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.11 EUR | +3.01% |
|
-0.84% | +10.63% |
| Feb. 15 | Transcript : Optomed Oyj, 2023 Earnings Call, Feb 15, 2024 | |
| Feb. 15 | Optomed Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 83.64 | 95.5 | 132.7 | 60.54 | 66.04 | 73.06 | - | - |
| Enterprise Value (EV) 1 | 75.81 | 91.41 | 132.9 | 57.29 | 62.27 | 74.03 | 77.64 | 73.06 |
| P/E ratio | -30.9 x | -30.1 x | -30.6 x | -10.1 x | -13.8 x | -18.7 x | -26.5 x | -411 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.58 x | 7.34 x | 8.93 x | 4.13 x | 4.37 x | 4.35 x | 2.88 x | 2.45 x |
| EV / Revenue | 5.06 x | 7.03 x | 8.95 x | 3.91 x | 4.12 x | 4.41 x | 3.06 x | 2.45 x |
| EV / EBITDA | -387 x | -125 x | -66.4 x | -29.4 x | -42.4 x | -40.1 x | 26.9 x | 25.2 x |
| EV / FCF | -59.5 x | -29.8 x | -39.1 x | -10.6 x | -75.2 x | -14.8 x | -23.5 x | -146 x |
| FCF Yield | -1.68% | -3.36% | -2.56% | -9.42% | -1.33% | -6.75% | -4.25% | -0.68% |
| Price to Book | 3.69 x | 4.78 x | 7.31 x | - | 3.24 x | 4.49 x | 5.41 x | - |
| Nbr of stocks (in thousands) | 13,192 | 13,227 | 13,539 | 16,167 | 17,776 | 17,776 | - | - |
| Reference price 2 | 6.340 | 7.220 | 9.800 | 3.745 | 3.715 | 4.110 | 4.110 | 4.110 |
| Announcement Date | 2/28/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14.98 | 13.01 | 14.85 | 14.66 | 15.1 | 16.79 | 25.35 | 29.8 |
| EBITDA 1 | -0.196 | -0.733 | -2.002 | -1.952 | -1.47 | -1.845 | 2.89 | 2.9 |
| EBIT 1 | -2.457 | -2.906 | -4.78 | -5.097 | -3.663 | -4.08 | 0.1667 | 0.3 |
| Operating Margin | -16.41% | -22.33% | -32.19% | -34.77% | -24.26% | -24.3% | 0.66% | 1.01% |
| Earnings before Tax (EBT) 1 | -2.952 | -3.247 | -4.327 | -5.551 | -4.519 | -4.02 | -2.835 | -0.1 |
| Net income 1 | -2.875 | -3.177 | -4.249 | -5.472 | -4.441 | -3.965 | -2.77 | -0.1 |
| Net margin | -19.2% | -24.42% | -28.61% | -37.33% | -29.41% | -23.62% | -10.93% | -0.34% |
| EPS 2 | -0.2053 | -0.2400 | -0.3200 | -0.3700 | -0.2700 | -0.2200 | -0.1550 | -0.0100 |
| Free Cash Flow 1 | -1.274 | -3.069 | -3.402 | -5.399 | -0.828 | -5 | -3.3 | -0.5 |
| FCF margin | -8.51% | -23.59% | -22.91% | -36.83% | -5.48% | -29.78% | -13.02% | -1.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.342 | 3.552 | 3.214 | 3.733 | 3.7 | 4.013 | 3.478 | 3.744 | 4.218 | 3.66 | 3.7 | 4 | 4.1 | 4.8 |
| EBITDA 1 | -0.337 | -1.528 | -0.937 | -0.813 | 0.145 | -0.347 | -0.513 | -0.462 | 0.263 | -0.757 | -0.5 | -0.4 | -0.8 | -0.8 |
| EBIT 1 | -0.888 | -2.182 | -1.461 | -1.355 | -1.411 | -0.87 | -1.043 | -1.009 | -0.603 | -1.319 | -1.1 | -1 | -1.3 | -1.4 |
| Operating Margin | -26.57% | -61.43% | -45.46% | -36.3% | -38.14% | -21.68% | -29.99% | -26.95% | -14.3% | -36.04% | -29.73% | -25% | -31.71% | -29.17% |
| Earnings before Tax (EBT) 1 | -0.853 | -1.956 | -1.39 | - | -1.397 | -1.417 | -1.177 | -1.334 | -0.459 | -1.55 | -1 | -0.9 | -1.3 | -1.4 |
| Net income 1 | -0.833 | -1.936 | -1.37 | - | -1.377 | -1.397 | -1.157 | -1.314 | -0.439 | -1.53 | -1 | -0.9 | -1.3 | -1.4 |
| Net margin | -24.93% | -54.5% | -42.63% | - | -37.22% | -34.81% | -33.27% | -35.1% | -10.41% | -41.8% | -27.03% | -22.5% | -31.71% | -29.17% |
| EPS 2 | -0.0600 | -0.1400 | -0.1000 | -0.1000 | -0.1000 | -0.1000 | -0.0800 | -0.0800 | -0.0300 | -0.0900 | -0.0600 | -0.0500 | -0.0700 | -0.0800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/17/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/17/23 | 5/5/23 | 8/4/23 | 11/3/23 | 2/15/24 | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.21 | - | - | 0.97 | 4.58 | - |
| Net Cash position 1 | 7.83 | 4.09 | - | 3.25 | 3.77 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.1064 x | - | - | -0.523 x | 1.583 x | - |
| Free Cash Flow 1 | -1.27 | -3.07 | -3.4 | -5.4 | -0.83 | -5 | -3.3 | -0.5 |
| ROE (net income / shareholders' equity) | -20.4% | -14.9% | -22.9% | -29.3% | -21.8% | -21.7% | -18.5% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.720 | 1.510 | 1.340 | - | 1.150 | 0.9200 | 0.7600 | - |
| Cash Flow per Share 2 | - | - | -0.2200 | -0.1600 | -0.0400 | -0.1500 | -0.0600 | - |
| Capex 1 | 0.26 | 0.27 | 2.57 | 3.03 | 2.41 | 2.3 | 2.3 | 2.5 |
| Capex / Sales | 1.74% | 2.06% | 17.33% | 20.66% | 15.97% | 13.7% | 9.07% | 8.39% |
| Announcement Date | 2/28/20 | 2/18/21 | 2/17/22 | 2/17/23 | 2/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.11
EUR
Average target price
5.8
EUR
Spread / Average Target
+41.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.63% | 78M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- OPTOMED Stock
- Financials Optomed Oyj
